SAN DIEGO, Jan. 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate Communications. As a seasoned communicator, Ms. Graham has more than 15 years of experience in the biopharmaceutical sector with expertise in growth companies and related transitions, such as the management of IPOs, financings and M&A activities, commercial product launches, and clinical development programs.
"Marcy brings substantial IR and communications expertise, and has a proven track record for building corporate brands and successfully integrating financials and marketing communications," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "She is a seasoned professional who will add significant value to Mirati as we advance our clinical programs."
Before joining Mirati, Ms. Graham was Vice President, Investor Relations and Corporate Communications at aTyr Pharma, participating in two major financings including their IPO in 2015. Previously, Ms. Graham served as head of Investor Relations and Corporate Communications at Ambit Biosciences until their acquisition by Daichi Sankyo in late 2014. Ms. Graham has extensive previous experience within other biopharmaceutical companies, including senior roles at Sequenom, Inc., and Genoptix, Inc.
About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.
Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, contain "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. For more detailed disclosures and discussions regarding such forward looking statements, please refer to Mirati's filings with the U.S. Securities and Exchange Commission ("SEC"), including without limitation Mirati's filings on Forms 10-K, 10-Q, and 8-K. Forward looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology, or by statements that certain actions, events or results "may" or "would" be taken, occur or be achieved. Such statements include, but are not limited to, statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates. Forward looking statements involve significant risks and uncertainties and are neither a prediction nor a guarantee that future events or circumstances will occur. Such risks include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks described in Mirati's filings with the SEC. We are including this cautionary note to make applicable, and to take advantage of, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The information in this news release is given as of the date above and Mirati expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-appoints-marcy-graham-vice-president-investor-relations-and-corporate-communications-300201401.html
SOURCE Mirati Therapeutics, Inc.
